Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy.

Autor:	Xu N; Children's Cancer Institute, University of New South Wales, Sydney, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia., Tse B; Children's Cancer Institute, University of New South Wales, Sydney, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia., Yang L; Children's Cancer Institute, University of New South Wales, Sydney, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia., Tang TCY; Children's Cancer Institute, University of New South Wales, Sydney, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia., Haber M; Children's Cancer Institute, University of New South Wales, Sydney, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia., Micklethwaite K; Blood Transplant and Cell Therapies Program, Department of Hematology, Westmead Hospital, Sydney, NSW, Australia.; Sydney Cellular Therapies Laboratory, NSW Health Pathology, Sydney, NSW, Australia.; Westmead Institute for Medical Research, Sydney, NSW, Australia.; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia., Dolnikov A; Children's Cancer Institute, University of New South Wales, Sydney, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia.
Jazyk:	angličtina
Zdroj:	ImmunoTargets and therapy [Immunotargets Ther] 2021 Apr 28; Vol. 10, pp. 123-140. Date of Electronic Publication: 2021 Apr 28 (Print Publication: 2021).
DOI:	10.2147/ITT.S296161
Abstrakt:	Purpose: Despite the success of chimeric antigen receptor (CAR) T cells in clinical studies, a significant proportion of responding patients eventually relapsed, with the latter correlating with low CAR T cell expansion and persistence. Methods and Results: Using patient-derived xenograft (PDX) mouse models of CD19 + B cell acute lymphoblastic leukemia (B-ALL), we show that priming leukemia-bearing mice with 5-azacytidine (AZA) enhances CAR T cell therapy. AZA given 1 day prior to CAR T cell infusion delayed leukemia growth and promoted CAR T cell expansion and effector function. Priming leukemia cells with AZA increased CAR T cell/target cell conjugation and target cell killing, promoted CAR T cell divisions and expanded IFNγ + effector T cells in co-cultures with CD19 + leukemia Nalm-6 and Raji cells. Transcriptome analysis revealed activation of diverse immune pathways in leukemia cells isolated from mice treated with AZA. We propose that epigenetic priming with AZA induces transcriptional changes that sensitize tumor cells to subsequent CAR T cell treatment. Among the candidate genes up-regulated by AZA is TNFSF4 which encodes OX40L, one of the strongest T cell co-stimulatory ligands. OX40L binds OX40, the TNF receptor superfamily member highly specific for activated T cells. TNFSF4 is heterogeneously expressed in a panel of pediatric PDXs, and high TNFSF4 expression correlated with increased CAR T cell numbers identified in co-cultures with individual PDXs. High OX40L expression in Nalm-6 cells increased their susceptibility to CAR T cell killing while OX40L blockade reduced leukemia cell killing. Conclusion: We propose that treatment with AZA activates OX40L/OX40 co-stimulatory signaling in CAR T cells. Our data suggest that the clinical use of AZA before CAR T cells could be considered. Competing Interests: The authors report no conflicts of interest in this work. (© 2021 Xu et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu